Aarti Drugs surged 9.72% to Rs 749.50 after the company's board approved a proposal to buyback upto 6 lakh equity shares of the firm at Rs 1000 each.
The board of the drug maker proposed to buyback upto 6 lakh equity shares of the company (equivalent to 0.64% of the total paid-up equity share capital of the company) at Rs 1000 apiece. The aggregate consideration of the buyback shall not exceed Rs 60 crore.
The buyback price is at a premium of 46.39% compared with Aarti Drugs' closing price of Rs 683.10 per shares recorded yesterday.
The board took note of intention of members of the promoter and promoter group including person in control of the company to participate in the proposed buyback.
The board of directors has determined the record date for the proposed buyback as 1 April 2021.
As on 12 March 2021, the promoter and promoter group held 60.2% stake in the company.
Aarti Drugs is a pharmaceutical company and has a strong presence in the anti-diarrhea, anti-inflammatory therapeutic groups.
The drug maker's consolidated net profit soared 144.9% to Rs 68.03 crore on 12% rise in net sales to Rs 530.25 crore in Q3 December 2020 over Q3 December 2019.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app